Evidence for immunosuppression by high-dose gammaglobulin

Area of Science:

• Immunology
• Cellular Immunity
• Immunotherapy

Background:

• High-dose immunoglobulin therapy is clinically effective for various autoimmune and inflammatory conditions.
• The precise mechanism of action for immunoglobulin therapy remains incompletely understood.
• Immunosuppression is a proposed mechanism for immunoglobulin therapy's efficacy.

Purpose of the Study:

• To investigate the immunosuppressive effects of high-dose immunoglobulin therapy.
• To identify the specific component of immunoglobulin responsible for immunosuppression.
• To elucidate the impact of immunoglobulin on key cellular immunity assays.

Main Methods:

• Assays for phytohemagglutinin (PHA) stimulation, mixed lymphocyte culture (MLC), natural killer (NK) cell activity, antibody-dependent cell-mediated cytotoxicity (ADCC), and cell-mediated lympholysis (CML) were performed.
• The inhibitory effects of immunoglobulin G (IgG) at concentrations 1.5-2 times normal were assessed.
• The inhibitory potential of Fc fragments compared to intact IgG was evaluated.

Main Results:

• High-dose immunoglobulin significantly inhibited PHA stimulation, MLC response, NK assay, ADCC, and CML.
• Inhibitory effects were observed at IgG concentrations 1.5-2 times above normal levels.
• Fc fragments demonstrated 100-1000 times greater inhibitory potency than intact IgG in PHA and MLC assays.

Conclusions:

• Immunoglobulin therapy likely exerts its effects through immunosuppression.
• The Fc portion of immunoglobulin is the primary mediator of this immunosuppressive activity.
• These findings highlight the Fc fragment's critical role in inhibiting cellular immune responses.